A Phase 3 Study of Efficacy and Safety of AK101 in Subjects With Psoriasis
Status:
Active, not recruiting
Trial end date:
2022-02-17
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, multicentered phase III clinical
study to evaluate the efficacy and safety of AK101 in the treatment of subjects with
moderate-to-severe plaque psoriasis.